[go: up one dir, main page]

MX2018000611A - Sistemas mejorados de entrega de nanoparticula. - Google Patents

Sistemas mejorados de entrega de nanoparticula.

Info

Publication number
MX2018000611A
MX2018000611A MX2018000611A MX2018000611A MX2018000611A MX 2018000611 A MX2018000611 A MX 2018000611A MX 2018000611 A MX2018000611 A MX 2018000611A MX 2018000611 A MX2018000611 A MX 2018000611A MX 2018000611 A MX2018000611 A MX 2018000611A
Authority
MX
Mexico
Prior art keywords
delivery systems
nanoparticle delivery
improved nanoparticle
therapeutic agents
combinations
Prior art date
Application number
MX2018000611A
Other languages
English (en)
Inventor
Wan Leon
Lui Winnie
Tardi Paul
Mayer Lawrence
Original Assignee
Celator Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celator Pharmaceuticals Inc filed Critical Celator Pharmaceuticals Inc
Publication of MX2018000611A publication Critical patent/MX2018000611A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Acá se describen composiciones de nanopartícula que comprenden combinaciones de profármacos de agentes terapéuticos que logran efectos terapéuticos mejorados en comparación con los observados cuando se administran combinaciones de formas libres de estos agentes terapéuticos.
MX2018000611A 2015-07-15 2016-07-14 Sistemas mejorados de entrega de nanoparticula. MX2018000611A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562192973P 2015-07-15 2015-07-15
US201562252396P 2015-11-06 2015-11-06
PCT/US2016/042330 WO2017011685A1 (en) 2015-07-15 2016-07-14 Improved nanoparticle delivery systems

Publications (1)

Publication Number Publication Date
MX2018000611A true MX2018000611A (es) 2018-09-06

Family

ID=57757767

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018000611A MX2018000611A (es) 2015-07-15 2016-07-14 Sistemas mejorados de entrega de nanoparticula.

Country Status (17)

Country Link
US (4) US10285951B2 (es)
EP (1) EP3322404A4 (es)
JP (2) JP2018521068A (es)
KR (1) KR20180029242A (es)
CN (1) CN107920985B (es)
AU (2) AU2016294617B2 (es)
BR (1) BR112018000217A2 (es)
CA (1) CA2991062C (es)
CO (1) CO2018000146A2 (es)
HK (1) HK1251159A1 (es)
IL (1) IL256797B (es)
MA (1) MA42458A (es)
MX (1) MX2018000611A (es)
RU (1) RU2018105494A (es)
SG (1) SG10201912394VA (es)
WO (1) WO2017011685A1 (es)
ZA (1) ZA201800130B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3021645A1 (en) 2016-04-29 2017-11-02 Icahn School Of Medicine At Mount Sinai Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
CN112218619A (zh) * 2017-11-20 2021-01-12 西奈山伊坎医学院 通过治疗性纳米生物制剂组合物抑制驯化免疫
EP3765089A4 (en) * 2018-03-16 2022-03-16 University of Massachusetts YEAST CELL WALL PARTICLE ENCAPSULATION OF BIODEGRADABLE PRO PAYLOADS
KR102088663B1 (ko) * 2018-03-20 2020-03-13 한국세라믹기술원 친수성 및 소수성 약물의 동시 전달을 위한 온도민감성 나노스펀지 플랫폼 및 이의 용도
WO2020123481A1 (en) * 2018-12-10 2020-06-18 Celator Pharmaceuticals Inc. Combination formulations of taxanes and mtor inhibitors
CN114401736A (zh) * 2019-08-13 2022-04-26 佩蒂诺沃生物制药公司 用于治疗伴随癌症治疗发生的化学疗法诱导的周围神经病变的palm
KR20230066582A (ko) * 2020-09-10 2023-05-16 남미 테라퓨틱스, 인크. 암의 치료에 유용한 pd-1 길항제 전구약물을 함유하는 제제화된 및/또는 공동-제제화된 리포솜 조성물 및 그의 방법
CN117355298A (zh) 2021-03-19 2024-01-05 生物治疗探索股份有限公司 用于调节训练免疫的化合物及其使用方法
WO2025199353A1 (en) * 2024-03-21 2025-09-25 Purdue Research Foundation Nanoparticulate formulations and foliar administration thereof in the treatment and prevention of citrus greening disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE345775T1 (de) * 2001-10-03 2006-12-15 Celator Pharmaceuticals Inc Zusammensetzungen zur verabreichung von arzneimittelkombinationen
AU2002350207A1 (en) * 2001-11-19 2003-06-10 Control Delivery Systems, Inc. Topical delivery of codrugs
CN1764375A (zh) * 2003-02-20 2006-04-26 康涅狄格大学健康中心 使用包括热休克蛋白或α－2－巨球蛋白的组合物治疗癌症和传染病的方法
US20080299205A1 (en) * 2004-07-19 2008-12-04 Mayer Lawrence D Particulate Constructs For Release of Active Agents
KR20080009196A (ko) * 2005-04-12 2008-01-25 위스콘신 얼럼나이 리서어치 화운데이션 중합체 및 패신저 약물의 마이셀 조성물
KR101563658B1 (ko) * 2007-11-28 2015-10-27 셀라토 파마슈티칼즈, 인코포레이티드 개선된 탁산 전달 시스템
EP2413901A4 (en) * 2009-03-30 2015-05-06 Cerulean Pharma Inc POLYMER CONCRETE CONJUGATES, PARTICLES, COMPOSITIONS AND CORRESPONDING USES
EP2499486A4 (en) * 2009-11-13 2013-11-27 Infinity Pharmaceuticals Inc COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, EVALUATION, PREVENTION, AND THERAPY OF CANCER
US20120052097A1 (en) * 2010-08-20 2012-03-01 Cerulean Pharma Inc. Therapeutic peptide-polymer conjugates, particles, compositions, and related methods
WO2012068468A1 (en) 2010-11-19 2012-05-24 Glaxosmithkline Llc Method of treatment with braf inhibitor
CN103501812A (zh) * 2011-04-29 2014-01-08 西莱克塔生物科技公司 用于过敏症治疗的致耐受性合成纳米载体
US20140308363A1 (en) * 2011-05-31 2014-10-16 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
DE102011109374A1 (de) * 2011-08-04 2013-02-07 Bock 1 Gmbh & Co. Kg Stuhl mit Wippmechanik
KR102062025B1 (ko) * 2014-06-30 2020-01-03 타베다 세라퓨틱스, 인코포레이티드 표적화된 콘주게이트 및 입자 및 그것의 제형

Also Published As

Publication number Publication date
CA2991062A1 (en) 2017-01-19
CN107920985A (zh) 2018-04-17
US20190209484A1 (en) 2019-07-11
US10285951B2 (en) 2019-05-14
IL256797B (en) 2021-05-31
AU2021286353A1 (en) 2022-01-20
IL256797A (en) 2018-06-28
HK1251159A1 (zh) 2019-01-25
CO2018000146A2 (es) 2018-04-19
JP2022033751A (ja) 2022-03-02
SG10201912394VA (en) 2020-02-27
KR20180029242A (ko) 2018-03-20
US20180207104A1 (en) 2018-07-26
RU2018105494A (ru) 2019-08-15
ZA201800130B (en) 2018-12-19
US11413253B2 (en) 2022-08-16
CA2991062C (en) 2023-06-20
JP2018521068A (ja) 2018-08-02
RU2018105494A3 (es) 2019-12-17
MA42458A (fr) 2018-05-23
AU2016294617A1 (en) 2018-01-25
EP3322404A4 (en) 2019-03-20
BR112018000217A2 (pt) 2018-09-04
CN107920985B (zh) 2022-03-01
US20240366519A1 (en) 2024-11-07
US20210052508A1 (en) 2021-02-25
EP3322404A1 (en) 2018-05-23
WO2017011685A1 (en) 2017-01-19
AU2016294617B2 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
MX2018000611A (es) Sistemas mejorados de entrega de nanoparticula.
ZA202004557B (en) Modulatory polynucleotides
ZA202308496B (en) Pharmaceutical compositions of therapeutically active compounds
MX2023010042A (es) Polinucleotidos moduladores.
PH12016500953A1 (en) Tricyclic compounds as anticancer agents
MX2015011897A (es) Profarmacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
PH12016501578A1 (en) Pharmaceutical compounds
PH12016501788A1 (en) Pharmaceutical compositions of therapeutically active compounds
MX2015011783A (es) Metodos para tratar tumores solidos pediatricos.
AU2016297823B2 (en) Methods for better delivery of active agents to tumors
MX2022001310A (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo.
MX382175B (es) Composiciones de profármaco de monometilfumarato
MX376782B (es) Métodos de administración de composiciones de amantadina.
MX2016007445A (es) Inhibidores de f1f0-atpasa de trifluorometil pirazolil guanidina y usos terapeuticos de los mismos.
PH12017502046A1 (en) Salts and prodrugs of 1-methyl-d-tryptophan
IN2013MU03918A (es)
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
IN2013MU03118A (es)
EP3881845A3 (en) Combination of trazodone and gabapentin for the treatment of pain
PH12018501166B1 (en) Concentrated gibberellin solution formulations
IN2013MU02469A (es)
NZ739679A (en) Cholecalciferol sulfate salts and their use for the treatment of vitamin d deficiency
IN2013MU03801A (es)
ZA201606135B (en) Pharmaceutical compositions of therapeutically active compounds
IN2013CH02437A (es)